Phaseline

Companies › SpyGlass Pharma

SpyGlass Pharma: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 2 Phase 3, 2 Phase 1, 1 Phase 4; Ophthalmology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bimatoprost
Prostanoid FP receptor agonist
PTGFRPhase 3Cataract; GlaucomaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06120842BimatoprostPhase 1CataractOphthalmologyNov 2027
NCT06120842BimatoprostPhase 1CataractOphthalmologyNov 2027
NCT07217678BimatoprostPhase 4GlaucomaOphthalmologyJan 2028
NCT07218783BimatoprostPhase 3CataractOphthalmologyMar 2029
NCT07218796BimatoprostPhase 3CataractOphthalmologyMay 2029

From the company's SEC filings

Cash of $223m on 2026-06-30; operating cash outflow about $58m a year; runway about 46 months at that burn, to May 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PTGFR (1)

Companies with the same targets

Glaukos YS Life Science Santen Pharmaceutical Triple Hair

Companies built like this

Santen Pharmaceutical YS Life Science EyePoint Pharmaceuticals AiViva BioPharma Ocular Therapeutix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.